Skip to main content

Recent Sentinel Activity

This recent activity feed provides a list of the last 90 days of Sentinel activity across assessments, publications & presentations, projects, events, etc.

RSS Feed

URL Title Category Date Recent Activity
https://www.sentinelinitiative.org/methods-data-tools/methods/covid-19-pregnancy-study-implementation COVID-19 Pregnancy Study Implementation Methods, Data, & Tools
COVID-19 Pregnancy Study Implementation
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/brilinta-ticagrelor Brilinta (Ticagrelor) & Concomitant Use with Lipitor (Atorvastatin) or Crestor (Rosuvastatin) Assessments
Brilinta (Ticagrelor) & Concomitant Use with Lipitor (Atorvastatin) or Crestor (Rosuvastatin)
Assessments
https://www.sentinelinitiative.org/studies/drugs/gimoti-metoclopramide Gimoti (Metoclopramide) & Duration of Use Assessments
Gimoti (Metoclopramide) & Duration of Use
Assessments
https://www.sentinelinitiative.org/methods-data-tools/methods/augmenting-date-death-cause-death-ascertainment-sentinel Augmenting Date of Death & Cause of Death Ascertainment in Sentinel Methods, Data, & Tools
Augmenting Date of Death & Cause of Death Ascertainment in Sentinel
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/mortality-following-long-acting-injectable-antipsychotics Mortality Following Long-Acting Injectable Antipsychotics Use: An Inverse Probability of Treatment Weighting Analysis Analyses
Mortality Following Long-Acting Injectable Antipsychotics Use: An Inverse Probability of Treatment Weighting Analysis
Analyses
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/2023-public-workshop-optimizing-use-postapproval-pregnancy 2023 Public Workshop: Optimizing the Use of Postapproval Pregnancy Safety Studies Sentinel Initiative Events
2023 Public Workshop: Optimizing the Use of Postapproval Pregnancy Safety Studies
Sentinel Initiative Events
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/covid-19-hospitalization-algorithm-defined-covid-19 COVID-19 Hospitalization Algorithm Defined in "COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis" Methods, Data, & Tools
COVID-19 Hospitalization Algorithm Defined in "COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/severe-covid-19-algorithm-defined-covid-19 Severe COVID-19 Algorithm Defined in "COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis" Methods, Data, & Tools
Severe COVID-19 Algorithm Defined in "COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/methods/characterization-covid-19-vaccination-data-sdd-0 Characterization of COVID-19 Vaccination Data in the SDD Methods, Data, & Tools
Characterization of COVID-19 Vaccination Data in the SDD
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/methods/development-and-refinement-toolkit-large-scale-covariate-adjustment Development and Refinement of a Toolkit for Large Scale Covariate Adjustment in the Electronic Health Record and Claims Data Partner Network Methods, Data, & Tools
Development and Refinement of a Toolkit for Large Scale Covariate Adjustment in the Electronic Health Record and Claims Data Partner Network
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/long-acting-injectable-antipsychotics Long-Acting Injectable Antipsychotics & Mortality Studies
Long-Acting Injectable Antipsychotics & Mortality
Studies
https://www.sentinelinitiative.org/news-events/publications-presentations/characterization-covid-19-vaccine-data-sentinel-system Characterization of COVID-19 Vaccine Data in the Sentinel System Publications and Presentations
Characterization of COVID-19 Vaccine Data in the Sentinel System
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-products-labeling-changes-related-pregnancy Utilization of Products with Labeling Changes Related to Pregnancy Among Mothers with Live-Birth Deliveries: A Descriptive Analysis Analyses
Utilization of Products with Labeling Changes Related to Pregnancy Among Mothers with Live-Birth Deliveries: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/brintellix-vortioxetine-and-brilinta-ticragelor Brintellix (Vortioxetine) and Brilinta (Ticragelor) & Medication Errors Studies
Brintellix (Vortioxetine) and Brilinta (Ticragelor) & Medication Errors
Studies
https://www.sentinelinitiative.org/studies/drugs/covid-19-pregnancy COVID-19 in Pregnancy & Drug Utilization, Disease Severity, Adverse Neonatal Outcomes, and Adverse Maternal Outcomes Studies
COVID-19 in Pregnancy & Drug Utilization, Disease Severity, Adverse Neonatal Outcomes, and Adverse Maternal Outcomes
Studies
https://www.sentinelinitiative.org/methods-data-tools/methods/comparison-signal-detection-and-evaluation-study-designs-inform Comparison of Signal Detection and Evaluation Study Designs to Inform Development of the Pregnancy Safety Framework Methods, Data, & Tools
Comparison of Signal Detection and Evaluation Study Designs to Inform Development of the Pregnancy Safety Framework
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/incidence-hospitalized-tachyarrhythmia-patients-type-2 Incidence of Hospitalized Tachyarrhythmia in Patients with Type 2 Diabetes Mellitus Using Tirzepatide or Other Long-Acting Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: A Descriptive Analysis Analyses
Incidence of Hospitalized Tachyarrhythmia in Patients with Type 2 Diabetes Mellitus Using Tirzepatide or Other Long-Acting Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/methods-data-tools/methods/chart-review-major-congenital-malformations Chart Review of Major Congenital Malformations Methods, Data, & Tools
Chart Review of Major Congenital Malformations
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/methods/use-case-2-uc2-aim-5-plasmode-simulation-based-quantitative-bias Use Case 2 (UC2) Aim 5: Plasmode Simulation Based Quantitative Bias Analysis (QBA) for Unmeasured Confounding Methods, Data, & Tools
Use Case 2 (UC2) Aim 5: Plasmode Simulation Based Quantitative Bias Analysis (QBA) for Unmeasured Confounding
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/biktarvy-bictegraviremtricitabinetenofovir-alafenamide Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) & Signal Identification Studies
Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) & Signal Identification
Studies
https://www.sentinelinitiative.org/methods-data-tools/methods/developing-prediction-model-estimate-magnitude-exposure Developing a Prediction Model to Estimate the Magnitude of Exposure Methods, Data, & Tools
Developing a Prediction Model to Estimate the Magnitude of Exposure
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/methods/use-case-2-uc2-aim-2-empirical-application-linked-dev-network-y5 Use Case 2 (UC2) Aim 2: Empirical Application of Linked Dev Network (Y5): Correcting Claims Analyses for Unmeasured Confounding Using Subset Calibration Tools Methods, Data, & Tools
Use Case 2 (UC2) Aim 2: Empirical Application of Linked Dev Network (Y5): Correcting Claims Analyses for Unmeasured Confounding Using Subset Calibration Tools
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/proton-pump-inhibitors Proton Pump Inhibitors & COVID-19 Hospitalization and Severe COVID-19 Studies
Proton Pump Inhibitors & COVID-19 Hospitalization and Severe COVID-19
Studies
https://www.sentinelinitiative.org/methods-data-tools/routine-querying-tools/sentinel-routine-querying-system-reporting-tool Sentinel Routine Querying System Reporting Tool Methods, Data, & Tools
Sentinel Routine Querying System Reporting Tool
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-covid-19-vaccinations-descriptive-analysis Characterization of COVID-19 Vaccinations: A Descriptive Analysis Modular Programs
Characterization of COVID-19 Vaccinations: A Descriptive Analysis
Modular Programs
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/covid-19-hospitalization-and-severe-covid-19-infection-1 COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Updated Inverse Probability of Treatment Weighting Analysis Analyses
COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Updated Inverse Probability of Treatment Weighting Analysis
Analyses
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/covid-19-hospitalization-algorithm-defined-covid-19-0 COVID-19 Hospitalization Algorithm Defined in "COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Updated Inverse Probability of Treatment Weighting Analysis" Methods, Data, & Tools
COVID-19 Hospitalization Algorithm Defined in "COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Updated Inverse Probability of Treatment Weighting Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/severe-covid-19-algorithm-defined-covid-19-0 Severe COVID-19 Algorithm Defined in "COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Updated Inverse Probability of Treatment Weighting Analysis" Methods, Data, & Tools
Severe COVID-19 Algorithm Defined in "COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Updated Inverse Probability of Treatment Weighting Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/uplizna-inebilizumab-cdon-0 Assessment of ARIA Sufficiency: Uplizna (inebilizumab-cdon) Sufficiency Assessments
Assessment of ARIA Sufficiency: Uplizna (inebilizumab-cdon)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/wayrilz-rilzabrutinib Assessment of ARIA Sufficiency: Wayrilz (rilzabrutinib) Sufficiency Assessments
Assessment of ARIA Sufficiency: Wayrilz (rilzabrutinib)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/mounjaro-tirzepatide Mounjaro (tirzepatide) & Arrhythmia Studies
Mounjaro (tirzepatide) & Arrhythmia
Studies
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/kesimpta-ofatumumab Assessment of ARIA Sufficiency: Kesimpta (ofatumumab) Sufficiency Assessments
Assessment of ARIA Sufficiency: Kesimpta (ofatumumab)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/lymphir-denileukin-diftitox-cxdl Assessment of ARIA Sufficiency: Lymphir (denileukin diftitox-cxdl) Sufficiency Assessments
Assessment of ARIA Sufficiency: Lymphir (denileukin diftitox-cxdl)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-amyloid-beta-directed-monoclonal-antibodies Utilization of Amyloid Beta-Directed Monoclonal Antibodies: A Descriptive Analysis Analyses
Utilization of Amyloid Beta-Directed Monoclonal Antibodies: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2018-third Duration of Follow Up for New Molecular Entities Approved in 2018: Third Descriptive Analysis Analyses
Duration of Follow Up for New Molecular Entities Approved in 2018: Third Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2020-second Duration of Follow Up for New Molecular Entities Approved 2020: Second Descriptive Analysis Analyses
Duration of Follow Up for New Molecular Entities Approved 2020: Second Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/new-molecular-entities-nmes New Molecular Entities (NMEs) & Utilization Characterization Studies
New Molecular Entities (NMEs) & Utilization Characterization
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2019-third Duration of Follow Up for New Molecular Entities Approved in 2019: Third Descriptive Analysis Analyses
Duration of Follow Up for New Molecular Entities Approved in 2019: Third Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/products-converted-labeling-reference-studies-pregnancy-and-lactation-rule Products with Converted Labeling Reference Studies for the Pregnancy and Lactation Rule for the Development of the Pregnancy Safety Study Framework & Use in Pregnancy Studies
Products with Converted Labeling Reference Studies for the Pregnancy and Lactation Rule for the Development of the Pregnancy Safety Study Framework & Use in Pregnancy
Studies
https://www.sentinelinitiative.org/studies/drugs/vabysmo-faricimab Vabysmo (Faricimab) & Signal Identification Studies
Vabysmo (Faricimab) & Signal Identification
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-faricimab-use-self-controlled Outcome Monitoring Following Faricimab Use: A Self-Controlled Risk Interval Signal Identification Analysis Analyses
Outcome Monitoring Following Faricimab Use: A Self-Controlled Risk Interval Signal Identification Analysis
Analyses
https://www.sentinelinitiative.org/methods-data-tools/methods/assessing-performance-major-congenital-malformations-composite-outcome Assessing the Performance of Major Congenital Malformations as a Composite Outcome in Signal Detection and Evaluation Methods, Data, & Tools
Assessing the Performance of Major Congenital Malformations as a Composite Outcome in Signal Detection and Evaluation
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/rhapsido-remibrutinib Assessment of ARIA Sufficiency: Rhapsido (remibrutinib) Sufficiency Assessments
Assessment of ARIA Sufficiency: Rhapsido (remibrutinib)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/semaglutide-injectables Semaglutide Injectables & Signal Identification Studies
Semaglutide Injectables & Signal Identification
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-semaglutide-use-self-controlled Outcome Monitoring Following Semaglutide Use: A Self-Controlled Risk Interval Signal Identification Analysis Analyses
Outcome Monitoring Following Semaglutide Use: A Self-Controlled Risk Interval Signal Identification Analysis
Analyses
https://www.sentinelinitiative.org/methods-data-tools/routine-querying-tools/sentinel-routine-querying-system Sentinel Routine Querying System Methods, Data, & Tools
Sentinel Routine Querying System
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/arakoda-tafenoquine-0 Assessment of ARIA Sufficiency: Arakoda (tafenoquine) Sufficiency Assessments
Assessment of ARIA Sufficiency: Arakoda (tafenoquine)
Sufficiency Assessments
https://www.sentinelinitiative.org/news-events/publications-presentations/adverse-outcomes-among-pregnant-women-covid-19-according Adverse Outcomes Among Pregnant Women with COVID-19 According to Hospitalization Status: A Prospective Individual Participant Data Meta-Analysis in Europe and North America Publications and Presentations
Adverse Outcomes Among Pregnant Women with COVID-19 According to Hospitalization Status: A Prospective Individual Participant Data Meta-Analysis in Europe and North America
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/medications-used-among-nonhospitalized-pregnant-women-covid Medications Used Among Nonhospitalized Pregnant Women With COVID-19: A Prospective Individual Patient Data Meta-Analysis in Europe and North America Publications and Presentations
Medications Used Among Nonhospitalized Pregnant Women With COVID-19: A Prospective Individual Patient Data Meta-Analysis in Europe and North America
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/augmenting-fact-and-date-death-electronic-health-records Augmenting Fact and Date of Death in Electronic Health Records Using Internet Media Sources: A Validation Study from Two Large Healthcare Systems Publications and Presentations
Augmenting Fact and Date of Death in Electronic Health Records Using Internet Media Sources: A Validation Study from Two Large Healthcare Systems
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/ocrevus-zunovo-ocrelizumab-and Assessment of ARIA Sufficiency: Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) Sufficiency Assessments
Assessment of ARIA Sufficiency: Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq)
Sufficiency Assessments